MicroBiotiX
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
It Mirae Tower 33 Digital-ro 9-gil 60-21...Phone Number
+82 263792649Website
www.microbiotix.netRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About MicroBiotiX
MicrobiotiX is a biotechnology company focused on developing bacteriophage and microbiome-based therapeutics to combat multidrug-resistant bacterial infections, autoimmune diseases, and various intractable conditions. They have a comprehensive bacteriophage library, meticulously researched over 15 years, targeting critical pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae. Additionally, MicrobiotiX operates a high-quality GMP facility to ensure regulatory-compliant production and excellence in product quality. Their intended clients include healthcare providers and patients affected by serious resistant infections and other complicated health conditions.Explore more
MicroBiotiX Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MicroBiotiX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if MicroBiotiX had a recent Job posting/layoffs
Earning: See what the market has to say on MicroBiotiX recently announced quarterly report
Check if MicroBiotiX has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at MicroBiotiX
Funding: Get notified immidiatlly once MicroBiotiX has new funding data
Check out if MicroBiotiX is spiking on competitors!
MicroBiotiX, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when MicroBiotiX launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at MicroBiotiX
Find more new buyers
Company Profile Activity
Activity Insights
MicroBiotiX is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MicroBiotiX is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MicroBiotiX.
MicroBiotiX financials insights
Gather financial insights about MicroBiotiX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series B
$14.3M
MicroBiotiX Tech Stack
A closer look at the technologies used by MicroBiotiX
See more technologies
MicroBiotiX News & Media
MicrobiotiX and West Africa Centre for Innovative Research and Care in Ghana Sign MoU to Advance Clinical Development of Bacteriophage Therapeutics and Combat AMR·MDR in Africa
MicrobiotiX and KATH sign MoU to advance clinical bacteriophage therapies against AMR·MDR and expand treatment options for patients in Africa.MicrobiotiX Receives IND Approval for Novel Bacteriophage Drug MP101
MicrobiotiX gains IND approval to initiate clinical trials for its pneumonia therapy designed to combat antibiotic-resistant superbugs.MicrobiotiX Finalizes KRW 20 Billion Series B, Securing Korea's First Bacteriophage Clinical Trial
MicrobiotiX raises KRW 20B Series B and wins grant to launch Korea’s first phage therapy trial, advancing fight against superbugs.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding MicroBiotiX
Sign Up For FreeTo access detailed company insights
MicrobiotiX is a biotechnology company focused on developing bacteriophage and microbiome-based therapeutics to combat multidrug-resistant bacterial infections, autoimmune diseases, and various intractable conditions. They have a comprehensive bacteriophage library, meticulously researched over 15 years, targeting critical pathogens such as Pseudom... Read More
